On March 24, the Oswaldo Cruz Foundation launched an express approval process in the Brazilian Registry of Clinical Trials (ReBEC) for clinical research on COVID-19. The so-called fast track may reduce the normal approval period, from up to a few weeks, to less than 48 hours. Scientists around the world will have quick access to modeling studies already underway, avoiding rework and favoring cooperation. The objective is to shorten the time between the beginning of the research, the testing and the arrival of medicines, vaccines and other innovations to society.

Fast track users will receive online support through four dedicated phone lines, using messages in free apps like Telegram or Whatsapp, or even through the chat provided by the platform. They will also be able to be answered via voice call via wi-fi, with a scheduled time per message, using the same applications. In addition to the 24-hour operating system with automated e-mail messages every day, human service will be expanded, starting earlier, at 8 am, and going until 8 pm. “Our curatorship and technology team accepted the challenge and will work in shifts to meet the demand, which today is spread around the world”, guaranteed Luiza Silva, coordinator of ReBEC and specialist in risk and crisis communication. The existing fast tracks - zika, dengue, yellow fever and malaria - and the attendance to other studies will not be interrupted.

The platform has more than 3,800 approved records, all of which have been validated by the most important scientific journals in the world and open to public consultation and is the only primary record in the world in Portuguese recognized by the World Health Organization.

ICICT/Fiocruz

https://portal.fiocruz.br/noticia/plataforma-brasileira-acelera-registro-para-estudos-sobre-covid-19